Claims for Patent: 5,880,136

Summary for Patent: 5,880,136

Title:	Sulfonamide fibrinogen receptor antagonists
Abstract:	A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.
Inventor(s):	Duggan; Mark E. (Narberth, PA), Egbertson; Melissa S. (Ambler, PA), Halczenko; Wasyl (Hatfield, PA), Hartman; George D. (Lansdale, PA), Laswell; William L. (Perkasie, PA)
Assignee:	Merck & Co., Inc. (Rahway, NJ)
Application Number:
Patent Claims:	1. A method for preventing thrombus formation in a mammal in need thereof, comprising administering an effective amount of a compound of the structural formula ##STR209## or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is aryl, C.sub.1-10 alkyl, or C.sub.4-10 aralkyl, wherein aryl is phenyl, pyridyl, thienyl, tetrazole or oxazole; R.sup.5 is ##STR210## wherein R.sup.8 is hydroxy or C.sub.1-10 alkyloxy, ##STR211## wherein R.sup.9 and R.sup.10 are selected from the group consisting of hydrogen, C.sub.1-10 alkyl and phenyl C.sub.1-4 alkyl; ##STR212## p is zero or one; and m is an integer from two to six, in combination with an effective amount of an anticoagulant agent. 2. A method of claim 1, wherein the compound has the structural formula ##STR213## or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is aryl, C.sub.1-10 alkyl, or C.sub.4-10 aralkyl, wherein aryl is phenyl, pyridyl, thiophenyl, tetrazole, or oxazole; R.sup.5 is ##STR214## wherein R.sup.8 is hydroxy or C.sub.1-10 alkyloxy, ##STR215## wherein R.sup.9 and R.sup.10 are selected from the group consisting of hydrogen, C.sub.1-10 alkyl and phenyl C.sub.1-4 alkyl; Z is O; p is zero or one; and m is an integer from two to six and the anticoagulant agent is selected from the group consisting of aspirin, heparin and warfarin. 3. A method of claim 2, wherein the compound is ##STR216## or a pharmaceutically acceptable salt thereof, and the anticoagulant agent is heparin. 4. The method of claim 3, wherein the salt is ##STR217##